Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 2691663

Complications with osseointegrated implants.

A D Sones
View original source ↗Export metadata ↓

Abstract

Complications with a predictable implant system are possible in spite of 20 years of longitudinal clinical study and a success rate of 90% to 95%. A potpourri of surgical and prosthodontic complications using the Branemark implant are presented and evaluated. Methods of avoiding prosthodontic complications due to implant placement are discussed. Component fractures are reviewed with special emphasis on reasons for failure. Esthetic and phonetic complications involving restoration of the maxillary arch are discussed with possible solutions.

Explore related subjects

Bone ResorptionBone ScrewsDental AbutmentsDental Implantation, EndosseousDental ImplantsDenture DesignEquipment FailureEsthetics, DentalHumansJaw, EdentulousSpeechJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A D Sones. 1989. Complications with osseointegrated implants.. https://doi.org/10.1016/0022-3913(89)90084-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

[A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].

The changes in the bone and in calcium metabolism during cisplatin or bisphosphonate administration is reported in a 50-year-old patient with esophageal carcinoma who had humoral hypercalcemia of malignancy (HHM). Laboratory findings on admission showed that ionized calcium was 1.65mmol/L, phosphorus was 2.4mg/dl, and PTH-rP was 151pmol/L, without any evidence of bone metastasis. After admission, cisplatin and/or bisphosphonate were administrated for hypercalcemia. These administrations ameliorated serum ionized calcium, urinary pyridinoline and hydroxyproline level within a few days. Although cisplatin administration decreased the serum osteocalcin level, bisphosphonate administration kept up the level, suggesting that bisphosphonate maintained bone formation and cisplatin decreased its formation. The discrepancy may be due to the coupling with the reduction of bone resorption and/or direct toxic effect on osteoblasts during cisplatin administration, and preservation of osteoblastic activity during bisphosphonate administration. Cisplatin and bisphosphonate may have different effects on bone formation. Serum 1,25(OH)2D level was slightly decreased or unchangeable after cisplatin administration, although the level was increased after bisphosphonate administration. Direct toxic effect on 1 alpha-hydroxylase of the kidney or increase in phosphrous level may explain the change of 1,25(OH)2D after cisplatin administration. These results suggested that cisplatin and bisphosphonate have the same effect of preventing bone resorption but different effects on bone formation and/or serum 1,25(OH)2D level.

Bone Resorption↗